Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease non-cystic fibrosis bronchiectasis (NCFB). The US regulator cleared DPP1 ...
The list of new medicines recommended for approval at the October meeting of the EMA's human medicines committee includes Brinsupri, the first treatment for serious chronic lung disease non-cystic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results